Article
Radiology, Nuclear Medicine & Medical Imaging
Huizi Keiko Li, Sumitaka Hasegawa
Summary: This study investigated the nuclear targeting activity of In-111-trastuzumab-NLS in a mouse model of intraperitoneal tumors, showing that the radio-immunoconjugate promotes more efficient tumor cell uptake and subsequent nuclear translocation.
NUCLEAR MEDICINE COMMUNICATIONS
(2022)
Article
Oncology
Zhongqiu Zhou, Zhuojun Zhang, Han Chen, Wenhao Bao, Xiangqin Kuang, Ping Zhou, Zhiqing Gao, Difeng Li, Xiaoyi Xie, Chunxiao Yang, Xuhong Chen, Jinyuan Pan, Ruiming Tang, Zhengfu Feng, Lihuan Zhou, Lan Wang, Jianan Yang, Lili Jiang
Summary: This study demonstrates that SBSN and secreted SBSN promote bladder cancer metastasis through activation of the EGFR/SRC/STAT3 pathway, identifying SBSN as a potential diagnostic and therapeutic target for bladder cancer.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Shinsaku Tokuda, Kenji Morimoto, Soichi Hirai, Yohei Matsui, Ryota Nakamura, Masaki Ishida, Hayato Kawachi, Kazue Yoneda, Kazutaka Hosoya, Takahiro Tsuji, Hiroaki Ozasa, Akihiro Yoshimura, Masahiro Iwasaku, Young Hak Kim, Mano Horinaka, Toshiyuki Sakai, Takahiro Utsumi, Shinsuke Shiotsu, Takayuki Takeda, Ryohei Katayama, Koichi Takayama
Summary: In this study, it was found that epidermal growth factor receptor (EGFR) signaling is involved in adaptive resistance to lorlatinib in ALK-rearranged NSCLC. EGFR inhibition enhanced ALK inhibition-induced apoptosis and halted the proliferation of ALK-rearranged lung cancer cells. Combination therapy with EGFR inhibitor and lorlatinib significantly suppressed tumor regrowth after cessation of treatment. This study provides new insights into tumor evolution and the development of combined therapeutic strategies for ALK-rearranged lung cancer.
NPJ PRECISION ONCOLOGY
(2023)
Article
Oncology
D. Rodriguez-Abreu, M. Cobo, S. Garcia-Roman, S. Viteri-Ramirez, N. Jordana-Ariza, B. Garcia-Pelaez, N. Reguart, A. Aguilar, J. Codony-Servat, A. Drozdowskyj, M. A. Molina-Vila, E. d'Hond, R. Rosell
Summary: The combination treatment of afatinib and anti-EGF vaccine shows good tolerability and anti-tumor activity in patients with EGFR mutations. After the immunization phase, patients exhibited high levels of anti-EGF antibodies and decreased EGF levels. Therefore, this combination therapy may enhance the clinical efficacy of EGFR TKIs.
Article
Multidisciplinary Sciences
Dmitry Kamashev, Maksim Sorokin, Irina Kochergina, Aleksey Drobyshev, Uliana Vladimirova, Marianna Zolotovskaia, Igor Vorotnikov, Nina Shaban, Mikhail Raevskiy, Denis Kuzmin, Anton Buzdin
Summary: The study found that many patients do not respond to EGFR-targeted therapeutics, requiring personalized diagnostics. Human serum can affect squamous carcinoma cell growth and EGFR drug response, with significant variation in effects observed across different experiments.
Article
Chemistry, Medicinal
Conrad Chan, Vanessa Prozzo, Sadaf Aghevlian, Raymond M. Reilly
Summary: A kit for preparing In-111[In]-BnDTPA-trastuzumab-NLS injection was successfully formulated under GMP conditions. The kit met all specifications and demonstrated good stability.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2022)
Article
Acoustics
Jia-Ling Ruan, Richard J. Browning, Yesna O. Yildiz, Luca Bau, Sukanta Kamila, Michael D. Gray, Lisa Folkes, Alix Hampson, Anthony P. McHale, John F. Callan, Borivoj Vojnovic, Anne E. Kiltie, Eleanor Stride
Summary: In this study, three different microbubble-based approaches for delivering the chemotherapy drug gemcitabine were compared. Among them, GembioMB showed a statistically significant increase in cleaved caspase 3 expression in the tumor cells, indicating gemcitabine-induced apoptosis.
ULTRASOUND IN MEDICINE AND BIOLOGY
(2021)
Article
Oncology
Jia-Ling Ruan, Richard J. Browning, Yesna O. Yildiz, Michael Gray, Luca Bau, Sukanta Kamila, James Thompson, Amy Elliott, Sean Smart, Anthony P. McHale, John F. Callan, Borivoj Vojnovic, Eleanor Stride, Anne E. Kiltie
Summary: This study investigates the use of ultrasound and microbubbles for targeted gemcitabine delivery to reduce normal-tissue toxicity in a murine orthotopic MIBC model. Results show a significant delay in tumor growth with both microbubble groups, while transient weight loss was observed but resolved within 10 days posttreatment. Ultrasound-mediated drug delivery methods did not exacerbate acute intestinal toxicity compared to conventional chemoradiation therapy.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chung Ying Chan, Zijun Chen, Gianluca Destro, Mathew Veal, Doreen Lau, Edward O'Neill, Gemma Dias, Michael Mosley, Veerle Kersemans, Florian Guibbal, Veronique Gouverneur, Bart Cornelissen
Summary: In this study, [F-18]rucaparib, a non-invasive PARP-targeting imaging agent, was developed for PET imaging of pancreatic cancer. The results showed its potential application value.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Edward O'Neill, Bart Cornelissen
Summary: Molecular radionuclide therapy is an effective treatment for tumors. Biomarkers can be used to identify tumor subtypes and dose-response relationships. However, the biological characteristics and heterogeneity of some tumors hinder further optimization of the treatment.
NUCLEAR MEDICINE AND BIOLOGY
(2022)
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Julie Nonnekens, Jean-Pierre Pouget, Bart Cornelissen, Samantha Y. A. Terry
NUCLEAR MEDICINE AND BIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Claudia Rose Fraser, Javier Ajenjo, Mathew Veal, Gemma Marie Dias, Chung Chan, Edward O'Neill, Gianluca Destro, Doreen Lau, Anna Pacelli, Veronique Gouverneur, Rebekka Hueting, Bart Cornelissen
Summary: In this study, the first F-18-labelled ATM inhibitor [F-18]1 was synthesized and its pharmacokinetics were evaluated in vitro and in vivo. The results showed that [F-18]1 specifically binds to ATM and has both advantages and limitations as an ATM inhibitor.
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Chung Ying Chan, Samantha L. Hopkins, Florian Guibbal, Anna Pacelli, Julia Baguna Torres, Michael Mosley, Doreen Lau, Patrick Isenegger, Zijun Chen, Thomas C. Wilson, Gemma Dias, Rebekka Hueting, Veronique Gouverneur, Bart Cornelissen
Summary: The injected mass of [F-Total]olaparib has a significant impact on tumor uptake, and moderate injected masses may lead to improved relative tumor uptake and tumor-to-background ratio for cancer diagnosis and radionuclide therapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Gianluca Destro, Zijun Chen, Chung Ying Chan, Claudia Fraser, Gemma Dias, Michael Mosley, Florian Guibbal, Veronique Gouverneur, Bart Cornelissen
Summary: Radioligand therapy (RLT) is a promising approach in cancer treatment. In this study, a new radiopharmaceutical, [123I]GD1, based on the PARP inhibitor rucaparib was synthesized and evaluated. [123I]GD1 showed potential as a theragnostic agent in both in vitro and in vivo models.
NUCLEAR MEDICINE AND BIOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Julie Bolcaen, Mohamed A. Gizawy, Samantha Y. A. Terry, Antonio Paulo, Bart Cornelissen, Aruna Korde, Jonathan Engle, Valery Radchenko, Roger W. Howell
Summary: Auger electron (AE) radiopharmaceutical therapy (RPT) may have therapeutic efficacy similar to α-particles for small oncologic diseases, with lower risks of normal tissue toxicity. Despite accumulating knowledge about AE research, the promise of AE RPT has not yet been realized, with only a few agents evaluated in clinical trials.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Medicine, Research & Experimental
Edward O'Neill, Michael Mosley, Bart Cornelissen
Summary: An effective absorbed dose response relationship has not yet been established for Lutetium-177 based radionuclide therapies. The inherent biological heterogeneity of neuroendocrine and prostate cancers may make it difficult to establish cohort-based dose-response relationships. Instead, an individual-based approach that monitors the dose-response within each tumor could provide a valuable metric for monitoring treatment efficacy.
Article
Chemistry, Inorganic & Nuclear
Anna C. Booth, Petra Vasko, M. Angeles Fuentes, Bart Cornelissen, Stephen Faulkner, Simon Aldridge
Summary: 1,8-Bis(boronic ester) derivatives of naphthalene, as receptors for fluoride ions through B-F-B chelation, are difficult to synthesize. However, unsymmetrical complexes with a bridging B-F-B motif have been successfully synthesized and shown to effectively uptake F- ions.
DALTON TRANSACTIONS
(2022)
Review
Chemistry, Medicinal
Jun Toyohara, Mohammed Al-Qahtani, Ya-Yao Huang, Emiliano Cazzola, Sergio Todde, Shozo Furumoto, Renata Mikolajczak, Clemens Decristoforo, Nic Gillings, Min Yang, Raymond Reilly, Adriano Duatti, Antonia Denkova, Ralf Schirrmacher, Giuseppe Carlucci, Yann Seimbille, Zhaofei Liu, Beverley Ellis, Bart T. Cornelissen, Klaus Kopka, Emerson Bernardes
Summary: This article introduces the highlight commentary released by the Editorial Board of EJNMMI Radiopharmacy and Chemistry, and the trends in the research field mentioned in these commentaries. The article mentions a series of different topics, including the application of novel radiochemistry and radiopharmaceuticals, as well as related PET labeling methods, FAPI tracers, and radionuclide therapy.
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2022)
Article
Biochemical Research Methods
Stephanie B. Hatch, Remko Prevo, Tiffany Chan, Val Millar, Bart Cornelissen, Geoff Higgins, Daniel Ebner
Summary: The protocol describes a high-throughput automated and high-content imaging approach for screening cell resistance in 96-well plate format, which can be applied across a broad range of cell types.
Correction
Chemistry, Medicinal
Javier Ajenjo, Gianluca Destro, Bart Cornelissen, Veronique Gouverneur
EJNMMI RADIOPHARMACY AND CHEMISTRY
(2022)